التفاصيل البيبلوغرافية
| العنوان: |
Pattern of anticoagulation prescription for patients with Covid-19 acute respiratory distress syndrome admitted to ICU. Does it impact outcome? |
| المؤلفون: |
Nadeem, Rashid, Thomas, Stelvie John, Fathima, Zoubia, Palathinkal, Anju Subin, Alkilani, Yazan Emad, Dejan, Efaf Ahmad, Darwish, Ismail mohammad ismail, Alsubousi, Aisha Ali, Backour, Allaa Marouf, Kandeel, Hussein, Omar, Mohamad, Kewan, Hesham Fawzy Yehia Taha, makhlof, Mahmod Elshahat, Kotgire, Anand Bhaskarrao |
| المصدر: |
Heart & Lung; Jan2021, Vol. 50 Issue 1, p1-5, 5p |
| مستخلص: |
• Covid-19 infection is associated with elevation of inflammatory markers and coagulopathy. • Anticoagulation practice for severely ill covid-19 patients is variable among physicians. • Inflammatory markers levels may impact anticoagulation dosages. • Anticoagulation does not improve 28-day survival. Covid-19 has affected 16Millions people worldwide with 644 K death as of July 26th, 2020. It is associated with inflammation and microvascular thrombosis—anticoagulation in widely used in these patients especially in patients with elevated d -Dimers. The significance of anticoagulation in these patients is not yet established. We aim to define the anticoagulation pattern and its impact on outcomes (28-day survival, LOSICU, DVT, and PE and bleeding complications. We also observe if levels of d -Dimers affect the anticoagulation prescription. Methods: We analyzed data of all consecutive patients with Covid-19 ARDS admitted to ICU retrospectively. The primary variable of interest was anticoagulation. The daily dose of anticoagulant medication for each patient was recorded. Survival (28-day survival), Length of stay in ICU (LOSICU), the occurrence of DVT, PE, or bleeding were primary outcome variables. We also recorded confounding factors with potential impact on clinical outcomes. We assign Patients to one of the four groups based on anticoagulant dosing during the ICU (increasing dose, decreasing dose, increase followed by a decrease, multiple changes). We analyze the effect of different anticoagulation dosing strategies on 28-day survival, LOSICU, the occurrence of DVT, PE, and bleeding. We also observe if levels of d -Dimers affect the anticoagulation prescription. Results: The sample includes 149 patients. The most frequently used medication was subcutaneous Enoxaparin (85.2%). The Enoxaparin mean dose per day for the whole sample was 49.5 mg + 15.7 (mean + SD). There was no significant difference in doses of anticoagulants between survivors and nonsurvivors (62.8 mg + 21.7 mg vs. 61.2 mg + 25.7 mg, p 0.3). Multinomial regression showed no difference in 28-day survival among four-dose modification (increasing dose, decreasing dose, increase followed by a decrease, multiple changes). Logistic regression showed that BMI, d -Dimers, platelets, and the use of mechanical ventilation predict 28-day survival. Kaplan-Meier Survival plots for 4 anticoagulant groups showed no survival advantage for any anticoagulant strategy. Secondary outcome analysis showed that d -dimer levels significantly affect anticoagulants doses. Conclusion: Prescription of anticoagulation is quite variable in patients admitted to ICU for Covid-19 associated ARDS. Anticoagulation dosing strategy has no significant effect on 28-day survival, LOSICU, the occurrence of DVT, PE, or bleeding. [ABSTRACT FROM AUTHOR] |
|
Copyright of Heart & Lung is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
